Vaccination using irradiated, genetically modified GM-CSF-secreting tumor cells has shown to induce an enhanced antitumor immunity in a phase 1/2 clinical trial alone or in association with chemotherapy in metastatic BC patients (104). Here, CSF2 is linked to breast cancer.